The government has approved a 30 per-cent trade margin cap on non-scheduled anti-cancer drugs, a move expected to reduce prices by up to 70% and save patients an estimated Rs 2,500 crore annually. An expert committee will finalise the medicines covered.
The government has expanded price controls on non-scheduled anti-cancer medicines by capping trade margins at 30 per cent of MRP. The move could reduce prices by up to 70 per cent, saving patients an estimated Rs 2,500 crore annually
The National Pharmaceutical Pricing Authority, the regulatory authority for medical devices and drugs, has allowed manufacturers and importers of knee implants to revise their costs for a period of one year, .i.e. till September 2024
The price monitoring and resource unit (PMRU) will function at the state level under the direct supervision of the state drug controller for increasing outreach of the NPPA
